Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.33 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1042399 | 1.00 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL1044115 | 1.00 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL3292729 | 0.99 | HSD17B10 (0.61) | HSD17B10TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL6414612 | 0.99 | HSD17B10 (0.61) | HSD17B10TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL3287063 | 0.99 | HSD17B10 (0.61) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL314687 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL5447002 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL6413992 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL9609762 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL1603028 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-07-04 | — | — | US | claimed |
| US-9902745-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2018-02-27 | — | — | US | claimed |
| WO-2018005759-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-01-04 | — | — | WO | claimed |
| EP-2384756-B1 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORP (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2384756-A2 | High-purity large-scale preparation of stannsoporfin | InfaCare Pharmaceutical Corporation (US) | 2011-11-09 | — | — | EP | claimed |
| EP-2079472-B1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | INFACARE PHARMACEUTICAL CORP (US) | 2011-09-14 | — | — | EP | claimed |
| US-7375216-B2 | Preparation of metal mesoporphyrin compounds | INFACARE PHARMACEUTICAL CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2021-08-03 | — | — | US | disclosed |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | MALLINCKRODT LLC | 2020-08-13 | — | — | US | disclosed |
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2020-05-26 | — | — | US | disclosed |
| US-10533024-B2 | Methods for synthesizing metal mesoporphyrins | MALLINCKRODT HOSPTIAL PRODUCTS IP LIMITED (IE) | 2020-01-14 | — | — | US | disclosed |
| CN-110279699-A | With the method for stannsoporfin treatment hyperbilirubinemia | 马林克罗特医疗产品知识产权公司 | 2019-09-27 | — | — | CN | disclosed |
| EP-3517115-A2 | METHODS FOR TREATING HYPERBILIRUBINEMIA WITH STANNSOPORFIN | InfaCare Pharmaceutical Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-1509527-A2 | PREPARATION OF METAL MESOPORPHYRIN HALIDE COMPOUNDS | Wellspring Pharmaceutical Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6818763-B2 | Preparation of metal mesoporphyrin halide compounds | WELLSPRING PHARMACEUTICAL CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040210048-A1 | Preparation of metal mesoporphyrin halide compounds | WELLSPRING PHARMACEUTICAL CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004045546-A2 | WATER-SOLUBLE MESOPORPHYRIN COMPOUNDS AND METHODS OF PREPARATION | WELLSPRING PHARMACEUTICAL CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097481-A1 | Water-soluble mesoporphyrin compounds and methods of preparation | WELLSPRING PHARMACEUTICAL CORPORATION | 2004-05-20 | — | — | US | disclosed |
| WO-2003101999-A2 | PREPARATION OF METAL MESOPORPHYRIN HALIDE COMPOUNDS | WELLSPRING PHARMACEUTICAL CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030225264-A1 | Preparation of metal mesoporphyrin halide compounds | SpecGx LLC | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | HDAC1 2667/4885EGFR 1970/4885HSD17B10 2207/4885 |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HDAC1 2667/4885EGFR 1970/4885HSD17B10 2207/4885 |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | HMOX1, HMOX2, PPOX | HDAC1 236/4885EGFR 3678/4885HSD17B10 703/4885 |
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | HDAC1 2667/4885EGFR 1970/4885HSD17B10 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.